百奥赛图-B（2315.HK）2025年业绩预告点评

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the benchmark index [2][8]. Core Insights - The company's main business is experiencing high growth driven by a robust antibody platform, which provides future flexibility and potential for expansion [1][8]. - For 2025, the company is projected to achieve revenue between 1.369 billion and 1.389 billion RMB, representing a year-on-year growth of 39.61% to 41.65%. The net profit attributable to shareholders is expected to be between 162 million and 182 million RMB, with a significant year-on-year increase of 384.26% to 443.88% [8]. - The report highlights the strong performance of the innovative animal models and preclinical CRO business, which are key drivers of revenue growth. The company has also made significant advancements in its antibody library and strategic partnerships, enhancing its competitive edge in the market [8]. Financial Forecasts - Revenue projections for the company are as follows: 1.376 billion RMB in 2025, 1.845 billion RMB in 2026, and 2.416 billion RMB in 2027, with corresponding growth rates of 40.4%, 34.1%, and 31.0% respectively [2][9]. - The net profit attributable to shareholders is forecasted to be 167 million RMB in 2025, 324 million RMB in 2026, and 530 million RMB in 2027, with growth rates of 399.3%, 93.3%, and 63.6% respectively [2][9]. - The report provides a detailed breakdown of the company's financial ratios, including a projected P/E ratio of 105 for 2025, decreasing to 33 by 2027, indicating improving valuation metrics over time [2][9].